Open AccessBacopa monnieri: Historical aspects to promising pharmacological actions for the treatment of central nervous system diseases
Author(s) -
Andréia Fuentes dos Santos,
Marília Moraes Queiroz Souza,
Karoline Bach Pauli,
Gustavo Ratti da Silva,
Midia Wolff Marques,
Pablo Alvarez Auth,
Wanessa de Campos Bortolucci,
Zilda Cristiani Gazim,
Giani Andrea Linde Colauto,
Nelson Barros Colauto,
Evellyn Claudia Wietzikoski Lovato,
Francislaine Aparecida dos Reis Lívero
Publication year - 2022
Publication title -
boletín latinoamericano y del caribe de plantas medicinales y aromáticas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.218
H-Index - 21
ISSN - 0717-7917
DOI - 10.37360/blacpma.22.21.2.09
Subject(s) - bacopa monnieri , medicine , central nervous system , disease , ethnobotany , traditional medicine , pharmacology , medicinal plants
Bacopa monnieri(L.) Wettst. (Plantaginaceae), also known as Brahmi, has been used to improve cognitive processes and intellectual functions that are related to the preservation of memory. The objective of this research is to review the ethnobotanical applications, phytochemical composition, toxicity and activity of B. monnieriin the central nervous system. It reviewed articles on B. monnieriusing Google Scholar, SciELO, Science Direct, Lilacs, Medline, and PubMed. Saponins are the main compounds in extracts of B. monnieri. Pharmacological studies showed that B. monnieriimproves learning and memory and presents biological effects against Alzheimer’s disease, Parkinson’s disease, epilepsy, and schizophrenia. No preclinical acute toxicity was reported. However, gastrointestinal side effects were reported in some healthy elderly individuals. Most studies with B. monnierihave been preclinical evaluations of cellular mechanisms in the central nervous system and further translational clinical research needs to be performed to evaluate the safety and efficacy of the plant.